• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, August 20, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Oncotarget: Enhancing doxorubicin anti-tumor efficacy and ameliorating cardiotoxicity

Bioengineer by Bioengineer
November 10, 2021
in Cancer
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Oncotarget published “Oncotarget: Enhancing doxorubicin anti-tumor efficacy and ameliorating cardiotoxicity” which reported that aerobic exercise is receiving increased recognition in oncology for its multiple purported benefits.

Aerobic exercise ameliorates doxorubicin-induced cardiotoxicity

Credit: Correspondence to – Zachary R. Wakefield – [email protected]

Oncotarget published “Oncotarget: Enhancing doxorubicin anti-tumor efficacy and ameliorating cardiotoxicity” which reported that aerobic exercise is receiving increased recognition in oncology for its multiple purported benefits.

Exercise is known to induce physiologic adaptations that improve patient quality-of-life parameters as well as all-cause mortality. However, the exercise prescription required to induce these beneficial tumor-related outcomes remains unclear.

This study characterized the aerobic adaptations to voluntary wheel running in normal tissues and the tumor microenvironment. However, intratumoral hypoxiaand global metabolism were altered in the tumors of exercising hosts relative to non-wheel running controls. Doxorubicin chemotherapy also was found to be more efficacious at delaying tumor growth with adjuvant aerobic exercise.

Dr. Zachary R. Wakefield from The University of Florida said, “Cancer presents a major public health concern both in the United States and worldwide.“

In females, breast cancer is the most commonly diagnosed malignancy and is responsible for the second most deaths across all cancer types.

Triple-negative breast cancer, characterized by the lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor 2, is a particularly aggressive subtype with poor outcomes. Aerobic exercise is intriguing as a potential adjuvant therapy for breast cancer. When implemented either during or after treatment, exercise has been shown to result in reduced adverse events, and to improve quality-of-life and aerobic respiratory fitness in cancer patients.

In addition, clinical trials have shown that exercise can decrease risk of breast cancer recurrence. Consequently, exercise recommendations are being adopted by major national and international cancer organizations. Still, the therapeutic potential of including exercise in clinical cancer management is far from fully realized. Emerging clinical data suggest that in addition to the known physical and psychological benefits, aerobic exercise may also improve cancer treatment efficacy and limit associated toxicity.

This may be of particular relevance for breast cancer survivors in whom cardiovascular disease is increasingly prevalent. Various chemotherapies are known to be cardiotoxic and doxorubicin, a highly prescribed chemotherapeutic agent for the treatment of breast cancer, has cumulative and dose-dependent cardiotoxic effects. Despite generally positive findings in regard to exercise and cancer outcomes, it remains unclear how to properly prescribe exercise. Here, the authors employed voluntary wheel running in orthotopic, syngeneic models of breast cancer in aged mice.

The Wakefield Research Team concluded in their Oncotarget Research Outputthat aerobic exercise improved doxorubicin’s anti-tumor efficacy, and also reduced its cardiotoxicity, implying that the inclusion of exercise in a therapeutic regimen led to a therapeutic gain. Modulation of either arm of the therapeutic index will positively affect patient outcomes, and exercise may uniquely affect both treatment efficacy and toxicity without additional side effects.

Sign up for free Altmetric alerts about this article

DOI – https://doi.org/10.18632/oncotarget.28057

Full text – https://www.oncotarget.com/article/28057/text/

Correspondence to – Zachary R. Wakefield – [email protected]

Keywords – aerobic exercise, breast cancer, hypoxia, doxorubicin, cardiotoxicity

About Oncotarget

Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget
Facebook – https://www.facebook.com/Oncotarget/
Twitter – https://twitter.com/oncotarget
LinkedIn – https://www.linkedin.com/company/oncotarget
Pinterest – https://www.pinterest.com/oncotarget/
Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
[email protected]
18009220957×105

Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC



Journal

Oncotarget

DOI

10.18632/oncotarget.28057

Article Title

“Oncotarget: Enhancing doxorubicin anti-tumor efficacy and ameliorating cardiotoxicity”

Share12Tweet7Share2ShareShareShare1

Related Posts

UTSW Clinical trial sets stage for new paradigm in kidney cancer treatment

UTSW Clinical trial sets stage for new paradigm in kidney cancer treatment

August 19, 2022
Anatomy of the kidneys, liver and heart with the inferior vena cava, and surgical intervention to treat cancer

Robotic kidney cancer surgery shows desirable outcomes in study

August 19, 2022

SUTD researchers leverage novel nanotechnology to control cells over long periods

August 18, 2022

Penn Medicine awarded $5.7 million NCI grant for new Cancer Telehealth Research Center of Excellence

August 18, 2022

POPULAR NEWS

  • Picture of the horse specimen.

    Ancient DNA clarifies the early history of American colonial horses

    57 shares
    Share 23 Tweet 14
  • Fatigue, headache among top lingering symptoms months after COVID

    40 shares
    Share 16 Tweet 10
  • Chi-Huey Wong awarded Tetrahedron Prize for Creativity in Organic Synthesis

    38 shares
    Share 15 Tweet 10
  • Dogs lying in the middle of the road after sunrise at Kewa Pueblo, in no hurry to start the day

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

WeaponryVaccinesUrbanizationUniversity of WashingtonZoology/Veterinary ScienceVehiclesViolence/CriminalsWeather/StormsVirologyVirusVaccineUrogenital System

Recent Posts

  • Harnessing the heart regeneration ability of marsupials
  • UTSW Clinical trial sets stage for new paradigm in kidney cancer treatment
  • Study: New model for predicting belief change
  • Rice, NASA extend Space Act Agreement
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In